57 related articles for article (PubMed ID: 23804077)
1. Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy.
Emeagi PU; Maenhout S; Dang N; Heirman C; Thielemans K; Breckpot K
Gene Ther; 2013 Nov; 20(11):1085-92. PubMed ID: 23804077
[TBL] [Abstract][Full Text] [Related]
2. Deletion of MyD88 in T Cells Improves Antitumor Activity in Melanoma.
Bayer AL; Padilla-Rolon D; Smolgovsky S; Hinds PW; Alcaide P
Am J Pathol; 2024 Jun; 194(6):1007-1019. PubMed ID: 38442804
[TBL] [Abstract][Full Text] [Related]
3. Adenoviral transduction of melanoma cells with B7-1: antitumor immunity and immunosuppressive factors.
Boxhorn HK; Smith JG; Chang YJ; Guerry D; Lee WM; Rodeck U; Turka LA; Eck SL
Cancer Immunol Immunother; 1998 Jul; 46(5):283-92. PubMed ID: 9690457
[TBL] [Abstract][Full Text] [Related]
4. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease.
Najem H; Marisetty A; Horbinski C; Long J; Huse JT; Glitza Oliva IC; Ferguson SD; Kumthekar PU; Wainwright DA; Chen P; Lesniak MS; Burks JK; Heimberger AB
Front Immunol; 2021; 12():745893. PubMed ID: 34691054
[TBL] [Abstract][Full Text] [Related]
5. SOCS1 favors the epithelial-mesenchymal transition in melanoma, promotes tumor progression and prevents antitumor immunity by PD-L1 expression.
Berzaghi R; Maia VS; Pereira FV; Melo FM; Guedes MS; Origassa CS; Scutti JB; Matsuo AL; Câmara NO; Rodrigues EG; Travassos LR
Sci Rep; 2017 Jan; 7():40585. PubMed ID: 28079159
[TBL] [Abstract][Full Text] [Related]
6. Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment.
Huo M; Zhao Y; Satterlee AB; Wang Y; Xu Y; Huang L
J Control Release; 2017 Jan; 245():81-94. PubMed ID: 27863995
[TBL] [Abstract][Full Text] [Related]
7. NRN1 interacts with Notch to increase oncogenic STAT3 signaling in melanoma.
Devitt L; Westphal D; Pieger K; Schneider N; Bosserhoff AK; Kuphal S
Cell Commun Signal; 2024 May; 22(1):256. PubMed ID: 38705997
[TBL] [Abstract][Full Text] [Related]
8. A knockdown of Maml1 that results in melanoma cell senescence promotes an innate and adaptive immune response.
Kang S; Xie J; Miao J; Li R; Liao W; Luo R
Cancer Immunol Immunother; 2013 Jan; 62(1):183-90. PubMed ID: 22864395
[TBL] [Abstract][Full Text] [Related]
9. The anthelmintic drug niclosamide induces apoptosis, impairs metastasis and reduces immunosuppressive cells in breast cancer model.
Ye T; Xiong Y; Yan Y; Xia Y; Song X; Liu L; Li D; Wang N; Zhang L; Zhu Y; Zeng J; Wei Y; Yu L
PLoS One; 2014; 9(1):e85887. PubMed ID: 24416452
[TBL] [Abstract][Full Text] [Related]
10. Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.
Fenton SE; Sosman JA; Chandra S
Cancer Drug Resist; 2019; 2(3):744-761. PubMed ID: 35582566
[TBL] [Abstract][Full Text] [Related]
11. Novel Immune Stimulant Amplifies Direct Tumoricidal Effect of Cancer Ablation Therapies and Their Systemic Antitumor Immune Efficacy.
Korbelik M; Hode T; Lam SSK; Chen WR
Cells; 2021 Feb; 10(3):. PubMed ID: 33668932
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Development of Exogenous dsRNA for the Induction of RNA Interference in Cancer Therapy.
Golubeva TS; Cherenko VA; Orishchenko KE
Molecules; 2021 Jan; 26(3):. PubMed ID: 33572762
[TBL] [Abstract][Full Text] [Related]
13. Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.
Yuan Y; Adam A; Zhao C; Chen H
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562324
[TBL] [Abstract][Full Text] [Related]
14. lncRNA RHPN1-AS1 Serves as a Sponge for miR-3133 Modulating the Cell Proliferation of Retinoblastoma through JAK2.
Li ZN; Ge MX; Cao LJ; Yuan ZF
Biomed Res Int; 2020; 2020():3502981. PubMed ID: 33426053
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticles as Smart Carriers for Enhanced Cancer Immunotherapy.
Thakur N; Thakur S; Chatterjee S; Das J; Sil PC
Front Chem; 2020; 8():597806. PubMed ID: 33409265
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
17. STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases.
Logotheti S; Pützer BM
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569642
[TBL] [Abstract][Full Text] [Related]
18. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment.
Qu Y; Dou B; Tan H; Feng Y; Wang N; Wang D
Mol Cancer; 2019 Mar; 18(1):69. PubMed ID: 30927928
[TBL] [Abstract][Full Text] [Related]
19. Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication.
Loh CY; Arya A; Naema AF; Wong WF; Sethi G; Looi CY
Front Oncol; 2019; 9():48. PubMed ID: 30847297
[TBL] [Abstract][Full Text] [Related]
20. The Journey of
Goyvaerts C; Breckpot K
Front Immunol; 2018; 9():2052. PubMed ID: 30254636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
